Atopic Dermatitis

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 6925 times

[level-membership-for-dermatology-category]10

Atopic Dermatitis

Introduction

• Common inflammatory skin disease that affects 10–25% of children and 2–10% of adults in most high-income and some low-income countries.

• Eczematous dermatitis characterized by intense pruritus and a chronic or chronically relapsing course.

• Sequelae often include sleep disturbances, psychological distress, disrupted family dynamics, and impaired functioning at school or work.

• Onset usually in infancy or early childhood, with development in the first year of life in >50% and before 5 years of age in >85% of affected individuals.

• Often accompanied by other atopic disorders such as asthma and allergic rhinoconjunctivitis (hay fever), which develop in an age-dependent sequence referred to as the atopic march (Fig. 10.1).

image

Fig. 10.1 The atopic march.

• Atopy is linked to the presence of allergen-specific serum IgE antibodies, which exist in ~70% of individuals who meet diagnostic criteria for atopic dermatitis (AD) (Table 10.1).

• The ‘hygiene hypothesis’ postulates that decreased exposure to infectious agents in early childhood increases susceptibility to atopic diseases.

• Both a genetic predisposition and environmental triggers (e.g., irritation, epicutaneous sensitization, microbial colonization) have pathogenic roles in AD.

• Loss-of-function variants in the filaggrin gene (FLG), which encodes a protein important to epidermal barrier function, represent a major predisposing factor for AD that is present in 20–50% of AD patients of European or Asian descent; these FLG variants are also implicated in ichthyosis vulgaris.

Clinical Features and Disease Stages of AD

• Pruritic eczematous lesions are often excoriated and exist on a spectrum of acuity:

– Acute lesions: edematous, erythematous papules and plaques that may have vesiculation, oozing, and crusting.

– Subacute lesions: erythematous patches or plaques with scaling and variable crusting.

– Chronic lesions: thickened plaques with lichenification (increased skin markings) as well as scaling.

• Small perifollicular papules (papular eczema) are especially common in patients with darkly pigmented skin.

• Regional variants of AD are depicted in Fig. 10.2.

• Post-inflammatory hyper-, hypo-, or (in severe cases) depigmentation may be seen upon resolution of AD lesions (Fig. 10.3).

• DDx: outlined in Table 10.2.

• AD is divided into infantile, childhood, and adolescent/adult stages with characteristic morphologies and distributions (see Fig. 10.2).

Associated Features of AD

Treatment of AD

• There are two major components to management of AD (Fig. 10.14).

– Treatment of active dermatitis with anti-inflammatory agent(s).

– Maintenance designed to improve skin barrier function, control subclinical inflammation, and avoid trigger factors.

• Proactive treatment of AD provides better long-term disease control and could potentially interrupt the atopic march.

• Basics of skin care.

– Daily luke-warm bath (preferred for infants/children) or shower with limited use of a mild cleanser.

– Within 3 minutes of exit from bath/shower, application of (1) a topical CS (or calcineurin inhibitor) when/where indicated; and then (2) liberal use of an emollient to the entire skin surface.

– Ointments (minimize stinging) and creams (less greasy) are preferred to lotions as emollients and should be applied twice daily; ceramide-dominant emollients may optimize barrier repair, whereas products containing lactic or glycolic acid can lead to stinging and should be avoided.

• Topical anti-inflammatory agents.

– First-line: topical CS of appropriate strength – higher potency for thick/lichenified plaques and lesions on hands/feet, lower potency for thinner lesions and body folds – used once or twice daily until eczema is completely clear.

• CS ointments (minimize stinging) and creams are generally preferred, but CS solutions, foams, and oils are useful for AD on the scalp.

• Addressing patients’/parents’ specific concerns about CS use helps to maximize adherence to the treatment plan.

• Tap water compresses followed by CS application or wet wraps after CS application can speed improvement of acute flares.

– Second-line: topical calcineurin inhibitors (TCIs; e.g., tacrolimus) are helpful primarily for thinner lesions on the face and in intertriginous areas.

– High-level maintenance with intermittent use of a topical CS and/or TCI (see Fig. 10.14) to usual sites of eczema once clear can help to control subclinical inflammation and prevent flares.

• Phototherapy and systemic anti-inflammatory agents.

– Narrowband UVB (often induces remission) > UVA1 (for acute flares) > UVA-broadband UVB combination.

– Systemic anti-inflammatory therapy should be restricted for severe, recalcitrant AD.

– Oral cyclosporine has the most evidence for efficacy, but its use is limited by potential side effects such as nephrotoxicity; other systemic agents (e.g., azathioprine, mycophenolate mofetil, methotrexate) have less dramatic benefit but better long-term safety profiles.

– Systemic CS therapy should be avoided due to the high likelihood of significant rebound flares (see Fig. 10.14) and the unacceptable side effects of long-term use; uncommon exception: severe acute flare (e.g., with a specific trigger) resistant to aggressive topical management – this short course of systemic CS must be transitioned to a topical regimen, phototherapy, or another systemic agent.

• Adjunctive pharmacologic therapy.

– Sedating antihistamines (e.g., hydroxyzine, diphenhydramine, doxepin) given at bedtime may help to break the itch–scratch cycle, especially if pruritus disrupts sleep.

– Controlled trials of nonsedating antihistamines, leukotriene antagonists, antibiotics (oral or topical) aimed at reducing colonization, and probiotics have not consistently demonstrated efficacy as treatments of AD; dilute sodium hypochlorite (bleach) baths may be of benefit (see Fig. 10.14).

For further information see Ch. 12. From Dermatology, Third Edition.

[/level-membership-for-dermatology-category][not-level-membership-for-dermatology-category]10

Atopic Dermatitis

Introduction

• Common inflammatory skin disease that affects 10–25% of children and 2–10% of adults in most high-income and some low-income countries.

• Eczematous dermatitis characterized by intense pruritus and a chronic or chronically relapsing course.

• Sequelae often include sleep disturbances, psychological distress, disrupted family dynamics, and impaired functioning at school or work.

• Onset usually in infancy or early childhood, with development in the first year of life in >50% and before 5 years of age in >85% of affected individuals.

• Often accompanied by other atopic disorders such as asthma and allergic rhinoconjunctivitis (hay fever), which develop in an age-dependent sequence referred to as the atopic march (Fig. 10.1).

image

Fig. 10.1 The atopic march.

• Atopy is linked to the presence of allergen-specific serum IgE antibodies, which exist in ~70% of individuals who meet diagnostic criteria for atopic dermatitis (AD) (Table 10.1).

• The ‘hygiene hypothesis’ postulates that decreased exposure to infectious agents in early childhood increases susceptibility to atopic diseases.

• Both a genetic predisposition and environmental triggers (e.g., irritation, epicutaneous sensitization, microbial colonization) have pathogenic roles in AD.

• Loss-of-function variants in the filaggrin gene (FLG), which encodes a protein important to epidermal barrier function, represent a major predisposing factor for AD that is present in 20–50% of AD patients of European or Asian descent; these FLG variants are also implicated in ichthyosis vulgaris.

Clinical Features and Disease Stages of AD

• Pruritic eczematous lesions are often excoriated and exist on a spectrum of acuity:

– Acute lesions: edematous, erythematous papules and plaques that may have vesiculation, oozing, and crusting.

– Subacute lesions: erythematous patches or plaques with scaling and variable crusting.

– Chronic lesions: thickened plaques with lichenification (increased skin markings) as well as scaling.

• Small perifollicular papules (papular eczema) are especially common in patients with darkly pigmented skin.

• Regional variants of AD are depicted in Fig. 10.2.

• Post-inflammatory hyper-, hypo-, or (in severe cases) depigmentation may be seen upon resolution of AD lesions (Fig. 10.3).

• DDx: outlined in Table 10.2.

• AD is divided into infantile, childhood, and adolescent/adult stages with characteristic morphologies and distributions (see Fig. 10.2).